EUR 1.4m grant for Gain Therapeutics

Please login or
register
26.07.2019
Molecule

Lugano-based Gain Therapeutics specializing in the discovery of new drugs for rare and CNS diseases has obtained €1.4 million from the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse.

Based in Lugano, Gain Therapeutics is a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in the central nervous system (CNS) diseases. The startup is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.

Gain Therapeutics announced that together with Dr Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.

The grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to severe clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the treatment of Gaucher Disease, GM1 Gangliosidosis and Parkinson’s Disease.

“We are proud of the Eurostars-2 grant notification, where Gain Therapeutics’ platform technology for identifying structurally targeted allosteric regulators has been very positively evaluated due to: clear unmet medical needs (and namely orphan, rare and defined diseases with a strong neurological need still unmet); novel platform technology developing brain penetrant small molecules able to restore misfolded lysosomal enzyme; a clearly defined path into a significant market; a balanced yet ambitious project with a strong IP estate,” said Dr. Manolo Bellotto, General Manager of Gain Therapeutics SA.

About the Eurostars programme

EUROSTARS is a joint initiative co-funded from the national budgets of 36 Eurostars and by the European Union through Horizon 2020. In the 2014-2020 period. The program has a total public budget of €1.14 billion.12-Sep-2019 The next Eurostars cut off is 12 September 2019.

(Press release)

0Comments

More news about

GT Gain Therapeutics SA

Company profiles on startup.ch

GT Gain Therapeutics SA

rss